Platform: Science & Pipeline

Synthetic Biology Platform Developing Targeted Therapeutics 

Human Fat/Lipids Absorption & Digestion

 Oral, Targeted, Non-Systemic

For decades researches and drug developers have been trying to find a solution for the western's world most growing epidemic: Metabolic Syndrome Diseases, such as Obesity, MASH and Hyperlipidemia. 

We engineer enzymes into oral and safe proprietary delivery mechanisms, which allow reduction of lipid accumulation in the blood and in the liver.

With our Non-systemic therapeutics, we strive to help patients reduce levels of toxicity from current therapeutics in the market. Allowing for increased efficacy, better safety profiles and higher tolerability. 

Current GLP1 and Statin therapies are helping millions of patients around the globe. However many millions of patients are intolerable to these current solutions and are either discontinuing or refusing these or are experiencing sever side effects. 

We work hard to develop safer more tolerable options for all patients, whether on any current therapies or ones that do not have a current tolerable choice. 

contact us: lital@purposebio.com